Tool Review

Pear Therapeutics (reSET, Somryst)

Pioneer FDA-cleared PDTs for SUD and insomnia - now operated by PursueCare and Nox Health post-bankruptcy.

Support Level
Self-Help
Pricing
Enterprise
Platforms
iOS, Android
Privacy
Not rated

Best For

  • Addiction treatment providers seeking FDA-cleared digital adjuncts
  • Sleep medicine physicians prescribing evidence-based insomnia treatment
  • Outpatient SUD programs wanting to extend care between visits

Not Recommended For

  • Organizations seeking comprehensive MBC platforms
  • Practices without prescribing capabilities
  • Those seeking direct insurance reimbursement (limited coverage)
Reviewed by HeyPsych Board· Last reviewed September 2026

About Pear Therapeutics (reSET, Somryst)

Pear Therapeutics pioneered prescription digital therapeutics (PDTs), becoming the first company to receive FDA approval for a mobile app treating substance use disorders when reSET was cleared in 2017. The company developed reSET for general substance use disorder, reSET-O for opioid use disorder, and Somryst for chronic insomnia - all using cognitive behavioral therapy techniques. Despite raising over $400 million and significant clinical validation, Pear filed for Chapter 11 bankruptcy in April 2023, citing slow reimbursement adoption and high costs. The company laid off 90%+ of employees and ceased accepting new prescriptions. In December 2023, PursueCare acquired reSET and reSET-O, now offering them for $90 out of pocket. Nox Health Group acquired Somryst. The products remain available to patients through their new owners.

Get Pear Therapeutics (reSET, Somryst)

Privacy & Security

Privacy Grade
Not rated
HIPAA Compliant
No
Data Sold
No

FAQ

About Pear Therapeutics (reSET, Somryst)

Pear Therapeutics filed for Chapter 11 bankruptcy in April 2023, citing slow reimbursement adoption and high costs. The company laid off 90%+ of employees. PursueCare acquired reSET and reSET-O in December 2023; Nox Health Group acquired Somryst.